English

Xenon Pharmaceuticals Inc.

EDGAR

XENE Quarterly report (10-Q) · filed 2026-08-06

57 filing records in this dataset, filed from 2014-09-10 to 2026-08-06. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

16 thousand USD

2017 Q4 · USD

Exact inputs and evidence

Revenue: 16000 USD Source

Operating margin

-50,318.75%

2017 Q4 · %

Exact inputs and evidence

Operating Income: -8051000 USD Source
Revenue: 16000 USD Source

Operating cash flow

-6.84 million USD

2017 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -28726000 USD Source
Operating Cash Flow: -21888000 USD Source

Free cash flow

-6.9 million USD

2017 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -28726000 USD Source
Operating Cash Flow: -21888000 USD Source
Capital Expenditure: 315000 USD Source
Capital Expenditure: 252000 USD Source

Cash and cash equivalents: 120 million USD 2026-06-30 Source
Exact value

119527000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 96.8 million shares 2026-06-30 Source
Exact value

96752884 shares

Reported share-count change

25.75% · 19.8 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

76939811 shares · 2025-06-30· Source
96752884 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

311 thousand USD

2017-01-01 – 2017-12-31

Exact inputs and evidence

Revenue: 16000 USD · 2017-01-01 – 2017-03-31 Source
Revenue: 15000 USD · 2017-04-01 – 2017-06-30 Source
Revenue: 264000 USD · 2017-07-01 – 2017-09-30 Source
Revenue: 16000 USD · 2017-10-01 – 2017-12-31 Source

Net income

-409 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -90896000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -345910000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -240649000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -102302000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -110736000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-338 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -197637000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -125885000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -279118000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -197637000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -88897000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -184287000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -88897000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

1.01 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 481000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 200000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 799000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 481000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 133000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 408000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 133000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-339 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -197637000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -125885000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -279118000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -197637000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -88897000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -184287000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -88897000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 481000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 200000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 799000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 481000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 133000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 408000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 133000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2017-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 111.58 million

Prior period

−USD 234.33 million

2024-01-01 – 2024-12-31
Current period

−USD 345.91 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-345910000 − -234330000 = -111580000 USD

-234330000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-345910000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Xenon Pharmaceuticals Inc. · 2025-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Year-over-year change in Net income: -111580000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -345910000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#3459158 Filing: 000119312526076650 Input fundies:NetIncome: -234330000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#3461044 Filing: 000119312526076650
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 97.73 million

Prior period

−USD 181.39 million

2024-01-01 – 2024-12-31
Current period

−USD 279.12 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-279118000 − -181389000 = -97729000 USD

-181389000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-279118000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Xenon Pharmaceuticals Inc. · 2025-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Year-over-year change in Operating cash flow: -97729000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -279118000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2063241 Filing: 000119312526076650 Input fundies:OperatingCashFlow: -181389000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2064996 Filing: 000119312526076650
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-74%

Prior period

USD 3.08 million

2024-01-01 – 2024-12-31
Current period

USD 799,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

799000 − 3075000 = -2276000 USD

3075000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
799000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Xenon Pharmaceuticals Inc. · 2025-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Year-over-year change in Capital expenditure: -2276000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 799000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2077055 Filing: 000119312526076650 Input fundies:CapitalExpenditure: 3075000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2078797 Filing: 000119312526076650
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2017 2017-01-01 – 2017-12-31

Revenue USD 311,000 100% of revenue
Operating costs Derived USD 32.89 million 10,574% of revenue
Operating income −USD 32.58 million −10,474% of revenue
Tax, interest and other Derived −USD 1.87 million −602% of revenue
Net income −USD 30.7 million −9,873% of revenue

Cash

Operating cash flow −USD 28.73 million −9,237% of revenue
Capital expenditure USD 315,000 101% of revenue
Free cash flow Derived −USD 29.04 million −9,338% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 1,476% of revenue.
2017 Operating loss: operating costs were 10,574% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	1803000	26620000 Derived	-24817000	-1820000 Derived	-22997000	-19846000 Derived	Source 2016-01-01 – 2016-12-31: 1803000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -24817000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -22997000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -19567000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 279000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	311000	32886000 Derived	-32575000	-1871000 Derived	-30704000	-29041000 Derived	Source 2017-01-01 – 2017-12-31: 311000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -32575000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -30704000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -28726000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 315000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 311K 2017

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Revenue	15577000	Revenue: 15577000 Open source
20162016-12-31	Revenue	1803000	Revenue: 1803000 Open source
20172017-12-31	Revenue	311000	Revenue: 311000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-82.8% 2017

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Year over year	No prior comparable period	Revenue: 15577000 Open source
20162016-12-31	Year over year	-88.4%	Revenue: 1803000 Open source Revenue: 15577000 Open source
20172017-12-31	Year over year	-82.8%	Revenue: 311000 Open source Revenue: 1803000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -10,474.3% 2017

Net margin -9,872.7% 2017

Free cash flow margin -9,337.9% 2017

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Operating margin	-60.1%	Operating Income: -9361000 Open source Revenue: 15577000 Open source
20162016-12-31	Operating margin	-1,376.4%	Operating Income: -24817000 Open source Revenue: 1803000 Open source
20172017-12-31	Operating margin	-10,474.3%	Operating Income: -32575000 Open source Revenue: 311000 Open source
20152015-12-31	Net margin	-101.1%	Net Income: -15752000 Open source Revenue: 15577000 Open source
20162016-12-31	Net margin	-1,275.5%	Net Income: -22997000 Open source Revenue: 1803000 Open source
20172017-12-31	Net margin	-9,872.7%	Net Income: -30704000 Open source Revenue: 311000 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 15577000 Open source
20162016-12-31	Free cash flow margin	-1,100.7%	Revenue: 1803000 Open source Operating Cash Flow: -19567000 Open source Capital Expenditure: 279000 Open source
20172017-12-31	Free cash flow margin	-9,337.9%	Revenue: 311000 Open source Operating Cash Flow: -28726000 Open source Capital Expenditure: 315000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -28.7M 2017

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Operating cash flow	Not reported	No source recorded
20162016-12-31	Operating cash flow	-19567000	Operating Cash Flow: -19567000 Open source
20172017-12-31	Operating cash flow	-28726000	Operating Cash Flow: -28726000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -29M 2017

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Free cash flow	Unavailable	No source recorded
20162016-12-31	Free cash flow	-19846000	Operating Cash Flow: -19567000 Open source Capital Expenditure: 279000 Open source
20172017-12-31	Free cash flow	-29041000	Operating Cash Flow: -28726000 Open source Capital Expenditure: 315000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

22.1% 2017

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Liabilities / assets	4.6%	Total Liabilities: 2915000 Open source Total Assets: 63949000 Open source
20162016-12-31	Liabilities / assets	5.3%	Total Liabilities: 3586000 Open source Total Assets: 67487000 Open source
20172017-12-31	Liabilities / assets	22.1%	Total Liabilities: 10187000 Open source Total Assets: 46121000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

10.98× 2017

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Current assets / current liabilities	21.88×	Current Assets: 60866000 Open source Current Liabilities: 2782000 Open source
20162016-12-31	Current assets / current liabilities	18.31×	Current Assets: 65675000 Open source Current Liabilities: 3586000 Open source
20172017-12-31	Current assets / current liabilities	10.98×	Current Assets: 44821000 Open source Current Liabilities: 4083000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 23 million Exact value Exact value: -22997000 USD 2016-01-01 – 2016-12-31: -22997000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Xenon Pharmaceuticals Inc. · 2016-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Net Income: -22997000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -22997000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459018004750/xene-20171231.xml#115155 Filing: 000156459018004750 The citation records this snapshot. The page link may show a newer release later.	−USD 19.57 million Exact value Exact value: -19567000 USD 2016-01-01 – 2016-12-31: -19567000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Xenon Pharmaceuticals Inc. · 2016-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Operating Cash Flow: -19567000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19567000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459018004750/xene-20171231.xml#137250 Filing: 000156459018004750 The citation records this snapshot. The page link may show a newer release later.	USD 279,000 Exact value Exact value: 279000 USD 2016-01-01 – 2016-12-31: 279000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Xenon Pharmaceuticals Inc. · 2016-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Capital Expenditure: 279000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 279000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459018004750/xene-20171231.xml#137963 Filing: 000156459018004750 The citation records this snapshot. The page link may show a newer release later.	−USD 19.85 million Calculation and evidence -19567000 − 279000 USD Exact free cash flow: -19846000 USD 2016-01-01 – 2016-12-31: -19567000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 279000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Xenon Pharmaceuticals Inc. · 2016-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Free cash flow: -19846000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19567000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459018004750/xene-20171231.xml#137250 Filing: 000156459018004750 Input fundies:CapitalExpenditure: 279000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459018004750/xene-20171231.xml#137963 Filing: 000156459018004750 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 30.7 million Exact value Exact value: -30704000 USD 2017-01-01 – 2017-12-31: -30704000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Xenon Pharmaceuticals Inc. · 2017-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Net Income: -30704000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30704000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459019006514/xene-20181231.xml#107504 Filing: 000156459019006514 The citation records this snapshot. The page link may show a newer release later.	−USD 28.73 million Exact value Exact value: -28726000 USD 2017-01-01 – 2017-12-31: -28726000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Xenon Pharmaceuticals Inc. · 2017-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Operating Cash Flow: -28726000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28726000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459019006514/xene-20181231.xml#127023 Filing: 000156459019006514 The citation records this snapshot. The page link may show a newer release later.	USD 315,000 Exact value Exact value: 315000 USD 2017-01-01 – 2017-12-31: 315000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Xenon Pharmaceuticals Inc. · 2017-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Capital Expenditure: 315000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 315000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459019006514/xene-20181231.xml#127444 Filing: 000156459019006514 The citation records this snapshot. The page link may show a newer release later.	−USD 29.04 million Calculation and evidence -28726000 − 315000 USD Exact free cash flow: -29041000 USD 2017-01-01 – 2017-12-31: -28726000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 315000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Xenon Pharmaceuticals Inc. · 2017-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Free cash flow: -29041000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28726000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459019006514/xene-20181231.xml#127023 Filing: 000156459019006514 Input fundies:CapitalExpenditure: 315000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459019006514/xene-20181231.xml#127444 Filing: 000156459019006514 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 34.5 million Exact value Exact value: -34497000 USD 2018-01-01 – 2018-12-31: -34497000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Xenon Pharmaceuticals Inc. · 2018-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Net Income: -34497000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -34497000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459020009385/xene-20191231.xml#155792 Filing: 000156459020009385 The citation records this snapshot. The page link may show a newer release later.	−USD 34.72 million Exact value Exact value: -34724000 USD 2018-01-01 – 2018-12-31: -34724000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Xenon Pharmaceuticals Inc. · 2018-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Operating Cash Flow: -34724000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -34724000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459020009385/xene-20191231.xml#176176 Filing: 000156459020009385 The citation records this snapshot. The page link may show a newer release later.	USD 507,000 Exact value Exact value: 507000 USD 2018-01-01 – 2018-12-31: 507000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Xenon Pharmaceuticals Inc. · 2018-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Capital Expenditure: 507000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 507000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459020009385/xene-20191231.xml#176598 Filing: 000156459020009385 The citation records this snapshot. The page link may show a newer release later.	−USD 35.23 million Calculation and evidence -34724000 − 507000 USD Exact free cash flow: -35231000 USD 2018-01-01 – 2018-12-31: -34724000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 507000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Xenon Pharmaceuticals Inc. · 2018-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Free cash flow: -35231000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -34724000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459020009385/xene-20191231.xml#176176 Filing: 000156459020009385 Input fundies:CapitalExpenditure: 507000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459020009385/xene-20191231.xml#176598 Filing: 000156459020009385 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 41.6 million Exact value Exact value: -41595000 USD 2019-01-01 – 2019-12-31: -41595000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Xenon Pharmaceuticals Inc. · 2019-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Net Income: -41595000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41595000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459021009905/xene-10k_20201231.htm#1666987 Filing: 000156459021009905 The citation records this snapshot. The page link may show a newer release later.	−USD 4.71 million Exact value Exact value: -4714000 USD 2019-01-01 – 2019-12-31: -4714000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Xenon Pharmaceuticals Inc. · 2019-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Operating Cash Flow: -4714000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4714000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459021009905/xene-10k_20201231.htm#1880100 Filing: 000156459021009905 The citation records this snapshot. The page link may show a newer release later.	USD 1.24 million Exact value Exact value: 1240000 USD 2019-01-01 – 2019-12-31: 1240000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Xenon Pharmaceuticals Inc. · 2019-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Capital Expenditure: 1240000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1240000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459021009905/xene-10k_20201231.htm#1892447 Filing: 000156459021009905 The citation records this snapshot. The page link may show a newer release later.	−USD 5.95 million Calculation and evidence -4714000 − 1240000 USD Exact free cash flow: -5954000 USD 2019-01-01 – 2019-12-31: -4714000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1240000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Xenon Pharmaceuticals Inc. · 2019-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Free cash flow: -5954000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4714000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459021009905/xene-10k_20201231.htm#1880100 Filing: 000156459021009905 Input fundies:CapitalExpenditure: 1240000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000156459021009905/xene-10k_20201231.htm#1892447 Filing: 000156459021009905 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 28.84 million Exact value Exact value: -28837000 USD 2020-01-01 – 2020-12-31: -28837000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Xenon Pharmaceuticals Inc. · 2020-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Net Income: -28837000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28837000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017023005582/xene-20221231.htm#2067714 Filing: 000095017023005582 The citation records this snapshot. The page link may show a newer release later.	−USD 48.12 million Exact value Exact value: -48124000 USD 2020-01-01 – 2020-12-31: -48124000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Xenon Pharmaceuticals Inc. · 2020-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Operating Cash Flow: -48124000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48124000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017023005582/xene-20221231.htm#2436342 Filing: 000095017023005582 The citation records this snapshot. The page link may show a newer release later.	USD 2.64 million Exact value Exact value: 2637000 USD 2020-01-01 – 2020-12-31: 2637000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Xenon Pharmaceuticals Inc. · 2020-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Capital Expenditure: 2637000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2637000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017023005582/xene-20221231.htm#2453182 Filing: 000095017023005582 The citation records this snapshot. The page link may show a newer release later.	−USD 50.76 million Calculation and evidence -48124000 − 2637000 USD Exact free cash flow: -50761000 USD 2020-01-01 – 2020-12-31: -48124000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 2637000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Xenon Pharmaceuticals Inc. · 2020-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Free cash flow: -50761000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48124000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017023005582/xene-20221231.htm#2436342 Filing: 000095017023005582 Input fundies:CapitalExpenditure: 2637000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017023005582/xene-20221231.htm#2453182 Filing: 000095017023005582 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 78.88 million Exact value Exact value: -78882000 USD 2021-01-01 – 2021-12-31: -78882000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Xenon Pharmaceuticals Inc. · 2021-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Net Income: -78882000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -78882000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017024023177/xene-20231231.htm#1545419 Filing: 000095017024023177 The citation records this snapshot. The page link may show a newer release later.	−USD 69.5 million Exact value Exact value: -69502000 USD 2021-01-01 – 2021-12-31: -69502000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Xenon Pharmaceuticals Inc. · 2021-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Operating Cash Flow: -69502000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -69502000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017024023177/xene-20231231.htm#1784605 Filing: 000095017024023177 The citation records this snapshot. The page link may show a newer release later.	USD 2.05 million Exact value Exact value: 2050000 USD 2021-01-01 – 2021-12-31: 2050000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Xenon Pharmaceuticals Inc. · 2021-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Capital Expenditure: 2050000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2050000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017024023177/xene-20231231.htm#1794770 Filing: 000095017024023177 The citation records this snapshot. The page link may show a newer release later.	−USD 71.55 million Calculation and evidence -69502000 − 2050000 USD Exact free cash flow: -71552000 USD 2021-01-01 – 2021-12-31: -69502000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 2050000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Xenon Pharmaceuticals Inc. · 2021-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Free cash flow: -71552000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -69502000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017024023177/xene-20231231.htm#1784605 Filing: 000095017024023177 Input fundies:CapitalExpenditure: 2050000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017024023177/xene-20231231.htm#1794770 Filing: 000095017024023177 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 125.37 million Exact value Exact value: -125373000 USD 2022-01-01 – 2022-12-31: -125373000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Xenon Pharmaceuticals Inc. · 2022-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Net Income: -125373000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -125373000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017025029149/xene-20241231.htm#3261311 Filing: 000095017025029149 The citation records this snapshot. The page link may show a newer release later.	−USD 101.03 million Exact value Exact value: -101028000 USD 2022-01-01 – 2022-12-31: -101028000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Xenon Pharmaceuticals Inc. · 2022-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Operating Cash Flow: -101028000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -101028000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017025029149/xene-20241231.htm#2044312 Filing: 000095017025029149 The citation records this snapshot. The page link may show a newer release later.	USD 2.89 million Exact value Exact value: 2894000 USD 2022-01-01 – 2022-12-31: 2894000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Xenon Pharmaceuticals Inc. · 2022-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Capital Expenditure: 2894000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2894000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017025029149/xene-20241231.htm#2057304 Filing: 000095017025029149 The citation records this snapshot. The page link may show a newer release later.	−USD 103.92 million Calculation and evidence -101028000 − 2894000 USD Exact free cash flow: -103922000 USD 2022-01-01 – 2022-12-31: -101028000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 2894000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Xenon Pharmaceuticals Inc. · 2022-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Free cash flow: -103922000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -101028000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017025029149/xene-20241231.htm#2044312 Filing: 000095017025029149 Input fundies:CapitalExpenditure: 2894000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000095017025029149/xene-20241231.htm#2057304 Filing: 000095017025029149 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 182.39 million Exact value Exact value: -182393000 USD 2023-01-01 – 2023-12-31: -182393000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Xenon Pharmaceuticals Inc. · 2023-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Net Income: -182393000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -182393000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#3462930 Filing: 000119312526076650 The citation records this snapshot. The page link may show a newer release later.	−USD 151.11 million Exact value Exact value: -151112000 USD 2023-01-01 – 2023-12-31: -151112000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Xenon Pharmaceuticals Inc. · 2023-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Operating Cash Flow: -151112000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -151112000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2066751 Filing: 000119312526076650 The citation records this snapshot. The page link may show a newer release later.	USD 5.62 million Exact value Exact value: 5617000 USD 2023-01-01 – 2023-12-31: 5617000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Xenon Pharmaceuticals Inc. · 2023-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Capital Expenditure: 5617000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5617000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2080541 Filing: 000119312526076650 The citation records this snapshot. The page link may show a newer release later.	−USD 156.73 million Calculation and evidence -151112000 − 5617000 USD Exact free cash flow: -156729000 USD 2023-01-01 – 2023-12-31: -151112000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 5617000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Xenon Pharmaceuticals Inc. · 2023-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Free cash flow: -156729000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -151112000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2066751 Filing: 000119312526076650 Input fundies:CapitalExpenditure: 5617000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2080541 Filing: 000119312526076650 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 234.33 million Exact value Exact value: -234330000 USD 2024-01-01 – 2024-12-31: -234330000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Xenon Pharmaceuticals Inc. · 2024-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Net Income: -234330000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -234330000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#3461044 Filing: 000119312526076650 The citation records this snapshot. The page link may show a newer release later.	−USD 181.39 million Exact value Exact value: -181389000 USD 2024-01-01 – 2024-12-31: -181389000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Xenon Pharmaceuticals Inc. · 2024-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Operating Cash Flow: -181389000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -181389000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2064996 Filing: 000119312526076650 The citation records this snapshot. The page link may show a newer release later.	USD 3.08 million Exact value Exact value: 3075000 USD 2024-01-01 – 2024-12-31: 3075000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Xenon Pharmaceuticals Inc. · 2024-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Capital Expenditure: 3075000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3075000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2078797 Filing: 000119312526076650 The citation records this snapshot. The page link may show a newer release later.	−USD 184.46 million Calculation and evidence -181389000 − 3075000 USD Exact free cash flow: -184464000 USD 2024-01-01 – 2024-12-31: -181389000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 3075000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Xenon Pharmaceuticals Inc. · 2024-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Free cash flow: -184464000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -181389000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2064996 Filing: 000119312526076650 Input fundies:CapitalExpenditure: 3075000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2078797 Filing: 000119312526076650 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 345.91 million Exact value Exact value: -345910000 USD 2025-01-01 – 2025-12-31: -345910000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Xenon Pharmaceuticals Inc. · 2025-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Net Income: -345910000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -345910000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#3459158 Filing: 000119312526076650 The citation records this snapshot. The page link may show a newer release later.	−USD 279.12 million Exact value Exact value: -279118000 USD 2025-01-01 – 2025-12-31: -279118000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Xenon Pharmaceuticals Inc. · 2025-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Operating Cash Flow: -279118000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -279118000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2063241 Filing: 000119312526076650 The citation records this snapshot. The page link may show a newer release later.	USD 799,000 Exact value Exact value: 799000 USD 2025-01-01 – 2025-12-31: 799000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Xenon Pharmaceuticals Inc. · 2025-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Capital Expenditure: 799000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 799000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2077055 Filing: 000119312526076650 The citation records this snapshot. The page link may show a newer release later.	−USD 279.92 million Calculation and evidence -279118000 − 799000 USD Exact free cash flow: -279917000 USD 2025-01-01 – 2025-12-31: -279118000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 799000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Xenon Pharmaceuticals Inc. · 2025-12-31 Xenon Pharmaceuticals Inc. (edgar:1582313) Free cash flow: -279917000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:25:19Z Snapshot: 33b7b66a2889735d7e6538515fbe4e4423834f951686ab8f023d7cbbe0d308cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1582313?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -279118000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2063241 Filing: 000119312526076650 Input fundies:CapitalExpenditure: 799000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm#2077055 Filing: 000119312526076650 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

57 filings · 3,011 latest values · 3,011 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001582313, 1582313, XENE, edgar:1582313

Also known as XENON PHARMACEUTICALS INC., Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2017 2017-01-01 – 2017-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation